

LUNG

THORACIC DISEASE SITE COMMITTEE

AGENDA OPEN SESSION

CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHILL A
SATURDAY APRIL 29, 2023, 1:30 – 4:00 PM (ET)

CO-CHAIRS: PENELOPE BRADBURY AND ALEX SUN
SENIOR INVESTIGATOR: PIERRE-OLIVIER GAUDREAU

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer
- To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group

1:30 pm	Welcome and Introduction	P.BrADBury/ A.Sun
1:35 pm	BR.31: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected NSCLC	G. Goss
1:45 pm	IND.227: A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (Phase II results and Phase III update)	Q. Chu
2:00 pm	BRC.7 (ECOG-ACRIN EA5163), INSIGNA: A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Non-squamous NSCLC with Immunobiomarker SIGNature-driven Analysis	A. Robinson
2:10 pm	BRC8 (S1827), MAVERICK: A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC	J. Greenland
2:20 pm	IND.238: A Phase II Study of Durvalumab Substudy A: In Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity Substudy B: For Continued Treatment (+/-) Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	P. Ellis
2:30 pm	Break	
2:50 pm	BR.36 (CRI-CCTG-0002): A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC	V. Anagnostou
3:10 pm	IND.242: Neoadjuvant Platform Trial in Patients with Surgically Resectable Non-Small Cell Lung Cancer	N. Blais
3:30 pm	<u>New proposals</u>	P.BrADBury/ A. Sun
4:00 pm	Meeting adjourned	

